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Chronic rhinosinusitis (CRS) is a common disease 
resulting from inflammation of the sinonasal mucosa. The 
underlying cause of the inflammation is multifactorial, with 
both genetic and environmental contributions1. Guidelines 
published by the AAOHNS in 2007 and a Cochrane review 
by Harvey et al. published in 2009 have clearly established 
the benefits of nasal saline irrigation for patients with 
CRS1,2. Benefits include improved mucociliary function, 
decreased nasal mucosal edema, and mechanical removal 
of infectious debris, allergens, mucus, and bacteria from the 
sinus and nasal cavities. Irrigation may also reduce reliance 
on other sinus medications, the number and frequency 
of acute exacerbations of CRS, and symptoms related to 
CRS. Side effects of saline irrigation are minimal and self-
limiting, mostly related to local irritation or ear symptoms.
Nasal Irrigation has also been recognized as a po-
tential route for topical drug administration into paranasal 
sinuses due to ease of use and direct drug effects on the 
sinonasal mucosa. Topical drugs being investigated for 
use in CRS include antimicrobial, anti-inflammatory and 
immunomodulatory agents. One difficult question for rhi-
nologists to answer is which patients with rhinosinusitis 
are the best candidates for topical approaches? Desired 
properties of all topical therapies include complete sinus 
distribution, high local drug absorption, low systemic ab-
sorption, and minimal toxicity to the cilia and sinonasal 
mucosa. Understandably, the benefits of saline irrigation 
and topical therapies are greatest in patients who have 
had prior functional endoscopic sinus surgery (FESS)3,4. 
Clinical studies support this finding, with distribution of 
topical solutions in the unoperated sinuses on the order of 
less than 2% of the total irrigation volume, with almost no 
penetration in the frontal and sphenoid sinuses4. For those 
patients with mucosal edema from infection and chronic 
inflammation, distribution is probably significantly less.
Oral and intravenous antimicrobial therapies have 
traditionally been prescribed to manage infectious exacer-
bations of CRS.  However, these agents are not without 
significant side effects, especially for patients requiring 
prolonged courses. Topically applied antibiotics in irriga-
tion have a theoretical advantage to localize high doses 
of antibiotics to the sinonasal mucosa while minimizing 
systemic side effects. The majority of clinical data for 
topical antibiotics has investigated and provided support 
for the use of mupirocin sinus irrigation for patients with 
MRSA infections5,6. Our lab investigated the use of topical 
tobramycin in a rabbit model of Pseudomonas sinusitis, 
and found that topical tobramycin resulted in the eradi-
cation of viable bacteria within the lumen of the sinus. 
However, even at high concentrations, topical tobramycin 
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could not eradicate Pseudomonas attached to the muco-
sa in biofilms7. Potential side effects of topical antibiotic 
therapy, such as vertigo or hearing loss, can be caused by 
either direct exposure to the middle ear or via systemic 
toxicity. Research has demonstrated systemic absorption 
and potential ototoxicity with aminoglycoside irrigation 
at commonly used concentrations8. For the antibacterial 
washes, the highest level of evidence currently exists for 
use in postsurgical patients and culture-directed therapy. 
However, despite the popularity and emergence of topical 
antibiotics for CRS as a treatment modality, there is curren-
tly only low-level evidence (Level III) supporting its use.
Biofilms have been identified as a potential risk 
factor for worse outcomes after endoscopic sinus surgery, 
persistent sinonasal inflammation, and a cause of recalci-
trant infections9,10. Traditional medical management for CRS 
is largely inadequate to eradicate sinonasal biofilms. Seve-
ral investigations have recently reported on topical agents 
to combat mucosal biofilms. Topical agents specifically 
proposed for the treatment of sinonasal biofilms in CRS 
have included mupirocin6, tobramycin11, moxifloxacin12, 
antimicrobial peptides13, iron chelators14, Manuka Honey15, 
and surfactants12,14,16,17. In vitro studies by Desrosiers et al. 
and Ha et al. were able to eliminate S. aureus biofilms 
with antibiotics in concentrations easily obtainable in to-
pical solutions12,18. However, enthusiasm for many of these 
therapies has been tempered by studies demonstrating 
by biofilm regrowth after treatment and ciliotoxic effects.
Surfactants in nasal irrigation have been shown to 
be effective for some patients with CRS.  Surfactants are 
thought to improve mucocilliary clearance by reducing the 
adherence of sputum to the epithelial layer which increases 
efficiency of energy transfer from the cilia to the mucus 
layer. We previously reported on the use of commercially 
available dilute baby shampoo irrigation in 18 patients 
with recalcitrant CRS. Almost half of patients in this study 
experiencing an overall improvement in their subjective 
symptoms, and 60% noting reductions in postnasal drai-
nage and thick mucus17. More recent investigations from 
our lab of a similar topical surfactant solution showed 
no ciliotoxicity or epithelial injury19. Future prospective, 
blinded and controlled studies are required to better un-
derstand the role of baby shampoo or other surfactants in 
the treatment of CRS.
Topical and oral steroids are commonly used to 
reduce sinonasal mucosal inflammation and to treat nasal 
polyps. Use of steroid irrigation has become more common 
to spare patients from the side effects and toxicities of 
systemic steroids, while providing higher concentrations 
of steroid directly to the sinus mucosa than what is pos-
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sible with topical nasal sprays. Various off-label mixtures 
have been described for irrigation, including mixtures of 
budesonide with saline at various concentrations20. Studies 
have shown that short-term use of steroid washes are 
well tolerated, without suppression of the hypothalamic-
pituitary-adrenal (HPA) axis21,22.
Despite increasing use of topical therapies for CRS, 
many questions remain regarding the optimal length of 
treatment, optimal delivery mechanism, and long-term 
effects of the treatments on the sinonasal mucosa and 
cilia. In addition, treatments with topical antibiotics, cor-
ticosteroids, and surfactants in combination could show 
synergistic benefits depending on the specific clinical 
presentation. Future studies will undoubtedly shed light 
on these questions, and provide more evidence of the 
efficacy of topical therapies for CRS.
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